

Edgar Filing: SANGUI BIOTECH INTERNATIONAL INC - Form NT 10-K

SANGUI BIOTECH INTERNATIONAL INC
Form NT 10-K
September 30, 2003

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 12b-25

NOTIFICATION OF LATE FILING

SEC FILE NUMBER
000-29233

CUSIP NUMBER
8010B1017

(Check One):

Form 10-K Form 20-K Form 10-Q Form N-SAR

For Period Ended: 6-30-2003

Transition Report on Form 10-K

Transition Report on Form 20-K

Transition Report on Form 11-K

Transition Report on Form 10-Q

Transition Report on Form N-SAR

For the Transition Period Ended: _____

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

Sangui Biotech International, Inc.

Full name of registrant

N/A

Former name if applicable

Edgar Filing: SANGUI BIOTECH INTERNATIONAL INC - Form NT 10-K

Alfred Herrhausen Street 44

Address of principal executive office (Street and number)

58455 Witten, Germany 58455

City, state and zip code

PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

- | (a) The reasons described in reasonable detail in Part III of this form
| could not be eliminated without unreasonable effort or expense;
|
- | (b) The subject annual report, semi-annual report, transition report on
| Form 10-K, 10-KSB, Form 20-F, 11-K, Form N-SAR, or portion thereof
[X] | will be filed on or before the 15th calendar day following the
| prescribed due date; or the subject quarterly report or transition
| report on Form 10-Q, 10-QSB, or portion thereof will be filed on or
| before the fifth calendar day following the prescribed due date; and
|
- | (c) The accountant's statement or other exhibit required by Rule
| 12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-k, 10-Q, N-SAR or the transition report or portion thereof, could not be filed within the prescribed time period.

The Registrant requires additional time to review and complete form 10-KSB. The Registrant will file its Annual Report on Form 10-KSB as soon as possible, and in any event no later than the fifteenth calendar day following the prescribed due date for such report.

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification.

Joachim Fleing +49 160 7412717

(Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months (or for such shorter) period that the registrant was required to file such reports) been filed? If answer is no, identify report(s). [X] Yes [] No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? [] Yes [X] No

Edgar Filing: SANGUI BIOTECH INTERNATIONAL INC - Form NT 10-K

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

Sangui Biotech International, Inc.

(Name of Registrant as Specified in Charter)

Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: September 30, 2003

/s/ Wolfgang K. Barnikol

Prof.Dr.Dr. Wolfgang K. Barnikol
President, Chief Executive and Chief
Financial Officer